October 2020 – Eternygen Announces the First Closing of its Series A2 Funding Round

Slider

Eternygen GmbH Press release, Berlin, October 26, 2020

Eternygen Announces the First Closing of its Series A2 Funding Round

Berlin, Germany, October 26,  2020 – Eternygen announces today the first closing of its Series A2 funding round led by new anchor investor Evotec SE and additional funding from venture capital firms Epidarex Capital, IBB Ventures and a number of family offices. The new investment amounting to €5M will be used to drive Eternygen’s development of novel treatments for non-alcoholic steatohepatitis (NASH) to the next milestone, i.e. the selection of a preclinical development candidate, the initiation of IND enabling studies as well as growing clinical capabilities within the team.

NASH is a life-threatening metabolic disease which urgently needs new effective treatment options and represents a large and rapidly growing market opportunity. Eternygen will use the proceeds of this financing to continue its preclinical program tackling NASH with a unique and previously unexplored mode of action by focusing on citrate metabolism, a key regulator for multiple processes driving NASH pathogenesis. Eternygen targets NaCT/SLC13A5 (also referred to as “INDY” or “I’m not dead yet) – a sodium coupled citrate transporter in the liver – which has a broad effect on NASH-relevant pathways like glucose metabolism, lipogenesis as well as inflammation, fibrosis and cardiovascular risk factors. The current funding round of about EUR 5m will remain open for additional investment to bring the program to clinical POC.

“NASH is expected to become one of the largest economic and public health burdens in developed countries over the next 10 years. Effective treatments are urgently needed to address this serious disease which can ultimately lead to liver cirrhosis,” Marco Janezic, Founder and CEO Eternygen, GmbH. “The ongoing support by our investors and the promising data generated to date give us great optimism to continue our work for patients and caregivers. In particular the commitment of Evotec as our main development partner, knowing the program in depth and now being the lead investor is a great validation of our recent work and gives us confidence for the next development stages of our unique approach,” he concluded.

“At Evotec we are committed to developing disease modifying treatments for metabolic diseases,” Dr. Cord Dohrmann, CSO Evotec said. “Eternygen’s approach to NASH fits very well as it is focused on the inhibition of INDY, a target with accumulating evidence that is plays an important metabolic role in the development of NASH and related metabolic disorders. Although INDY is not easily tractable via small molecules Eternygen has managed to identify a number of chemical leads which clearly have the potential to be turned into drugs. We are very much encouraged by Eternygen’s progress and believe that they will deliver sorely needed drugs to NASH patients who are lacking effective treatment options.”

ABOUT EPIDAREX CAPITAL

Epidarex Capital is a transatlantic venture capital firm with a track record of building exceptional life science companies in emerging hubs in the US and UK. Epidarex’s experienced team of early stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in the global healthcare market. For more information visit: https://epidarex.com

ABOUT EVOTEC SE

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

ABOUT IBB VENTURES

IBB Ventures (www.ibbventures.de) has been providing venture capital to innovative Berlin-based companies since 1997 and has established itself as the market leader in early stage financing. The funds are primarily used for development and market launch of innovative products or services as well as for business concepts from creative industries. Two funds with a total volume of EUR 100 million are currently in the investment phase. Both VC funds are financed by the Investitionsbank Berlin (IBB) and the European Regional Development Fund (ERDF), managed by the State of Berlin. IBB Ventures has already invested in more than 210 creative and technology companies in Berlin; in syndicates with partners, the start-ups received approx. EUR 1.52 billion, of which IBB Ventures has invested EUR 217 million as lead, co-lead or co-investor.          

ABOUT ETERNYGEN GMBH

Eternygen is a Berlin-based Biotech Company founded in June 2012 to focus on the research, development and marketing of NaCT inhibitors for the treatment of dietary-related metabolic diseases. The founding team consists of renowned scientists from leading German universities and academic institutes as well as serial entrepreneurs from the venture and industry community. Eternygen is a virtual company supported by a network of senior industry experts and contract research organizations. Eternygen shareholders include Epidarex Capital, Evotec SE, VC Fonds Technologie, Berlin, Germany managed by IBB Beteiligungsgesellschaft mbH, and two renowned family offices. For additional information please go to www.eternygen.com

CONTACT INFORMATION

Eternygen:
Marco Janezic, CEO. Ph. +49 30 1207 6983 – 0; email: m.janezic@eternygen.com
Dr. Grit Zahn, Head of Research. Ph. +49 30 1207 6983 – 1; email: g.zahn@eternygen.com

MC Services:
Catherine Featherston/Raimund Gabriel; Ph.. +49 89 210 228 – 80; eternygen@mc-services.eu

April 2020 – Eternygen is nominated for the “German Accelerator Life Sciences” programme

Slider

April 2020 – Eternygen is nominated for the “German Accelerator Life Sciences” programme

Link

April 2020 – Eternygen is presenting at „BioLaunchPad, the company showcase platform of BioTrinity” from 28 April – 1 May 2020.

Slider

Eternygen is presenting at „BioLaunchPad, the company showcase platform of BioTrinity” from 28 April – 1 May 2020.

Link

March 2020 – Dr. Grit Zahn, Head of Research of Eternygen GmbH presents at the 4th International SLC13A5 Deficiency Research Roundtable of the Tess research foundation in March 2020.

Slider

Dr. Grit Zahn, Head of Research of Eternygen GmbH presents at the 4th International SLC13A5 Deficiency Research Roundtable of the Tess research foundation.

Link

February 2020 – Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH

Slider

Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH

Press statement

Meet Eternygen at the Biotech Showcase conference 2020 in San Francisco, CA, USA

Slider

Meet Eternygen at the Biotech Showcase conference 2020 in San Francisco, CA, USA

Eternygen is attending the Biotech Showcase conference January 13–15, 2020  in San Francisco, CA, USA

Meet Eternygen at BioEurope conference in Hamburg from November 11th to 13th 2019

Slider

Meet Eternygen at BioEurope conference in Hamburg from November 11th to 13th

Eternygen will attend the BioEurope conference in Hamburg from 11th -13th. of November.

Prof. Birkenfeld was appointed as Chair of Medicine and Director of the Department of Diabetology, Endocrinology and Nephrology at the University Clinic Tübingen

Slider

Prof. Birkenfeld was appointed as Chair of Medicine and Director of the Department of Diabetology, Endocrinology and Nephrology at the University Clinic Tübingen

Since 1st of October 2019 Prof. Birkenfeld is Chair of Medicine and Director of the Department of Diabetology, Endocrinology and Nephrology at the University Clinic Tübingen. He also leads the Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University Tübingen.

Prof. Birkenfeld was awarded with the Abstract Award

Slider

Prof. Birkenfeld was awarded with the Abstract Award

Prof. Birkenfeld was awarded with the Abstract Award by the American College of Cardiology (ACC)

Eternygen at BioFIT 2017

Slider

Eternygen at BioFIT 2017

Eternygen was invited to join panel discussion at BioFIT 2017 conference “How are collaborations key to improve innovation in metabolic diseases?” in Strasbourg (28 – 29 November 2017)

(BioFIT programme)

Prof. Birkenfeld is chairman of the working group diabetes and heart

Slider

Prof. Birkenfeld is chairman of the working group diabetes and heart

Prof. Birkenfeld is the new chairman of the working group “diabetes and heart” of the Germany Diabetes Association (Link in German only)

Eternygen GmbH is part of the Network for Pharma Solutions (NetPhaSol, Germany)

Slider

Eternygen GmbH is part of the Network for Pharma Solutions (NetPhaSol, Germany)

Press release

Eternygen GmbH closes € 8.0 (US$ 8.3) million Series A financing

Slider

Eternygen GmbH closes € 8.0 (US$ 8.3) million Series A financing

Eternygen GmbH Closes € 8.0 (US$ 8.3) million Series A financing led by Epidarex Capital

Press release

Prof. Jordan takes on position as Head of the Institute of Aerospace Medicine

Slider

Prof. Jordan takes on position as Head of the Institute of Aerospace Medicine

“Prof. Jordan takes on position as Head of the Institute of Aerospace Medicine starting on 1st of December 2016 at the German Aerospace Center in Cologne”

TransCampus Network between TU Dresden and King’s College London receives €5million grant

Slider

TransCampus Network between TU Dresden and King’s College London receives €5million grant

The TransCampus network between King’s and Technische Universität Dresden (TUD) has been awarded a €5million grant (press release) 

Eteryngen at 7th International IQPC Conference

Slider

Eteryngen at 7th International IQPC Conference

Eternygen GmbH today announced that its head of research will present at the 7th International IQPC Conference “Clinically Relevant Drug Transporter”
June 21-23, 2016 to be held at the Hotel Palace in Berlin Germany.

Download press release 

Prof. Birkenfeld to take over the succession of Prof. Markolf Hanefeld at centre of clinical studies in Dresden

Slider

Prof. Birkenfeld to take over the succession of Prof. Markolf Hanefeld at centre of clinical studies in Dresden

Interview by GWT with Prof. Birkenfeld (in German)

Prof. Jordan receives renowned Peter Sleight Award

Slider

Prof. Jordan receives renowned Peter Sleight Award

Prof. Jordan receives renowned Peter Sleight Award of the european society of Hypertension (ESH)

Press statement of MHH (in German)

Factsheet in Das Ärzteblatt (in German)

Prof. Birkenfeld to receive renowned Ferdinand Bertram price

Slider

Prof. Birkenfeld to receive renowned Ferdinand Bertram price

Press statement of GWT (in German)

Article in Sächsische Zeitung (in German)

BioEquity Europe Conference

Slider

BioEquity Europe Conference

Eternygen GmbH will present a corporate overview of the company at the 16 th BioEquity Europe Conference, May 19-20, 2015 “Next Wave Companies” to be held at the Hotel InterContinental in Vienna, Austria. Presentation held by Dr. Grit Zahn.

download press statement
further information

Creation of a Transcampus between TU Dresden and King’s College London

Slider

Creation of a Transcampus between TU Dresden and King’s College London

PubMed Article

Introduction of Transcampus Initiative by King’s College London

Prof. Birkenfeld transfers to TU Dresden

Slider

Prof. Birkenfeld transfers to TU Dresden

Press statement GWT (in German) 

Evotec and Eternygen Cooperation

Slider

Evotec and Eternygen Cooperation

Evotec and Eternygen enter collaboration to identify and develop novel metabolic disease therapy.

download press statement

Dr. Grit Zahn new head of research

Slider

Dr. Grit Zahn new head of research

Eternygen appoints Dr. Grit Zahn as Head of Research.

download press statement

Eternygen GmbH receives funding

Slider

Eternygen GmbH receives funding

Eternygen GmbH receives funding from IBB Beteiligungsgesellschaft.

download press statement